Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -155.34% is 43% below its 5-year average of -108.26%, around the middle of its 5-year range (-335.02%–-34.84%).
As of the fiscal period ended Tuesday, June 30, 2026. 30.60% above its 12-month average of -223.83%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -155.34%.
RETURN ON EQUITY (ROE)
-155.34%
RETURN ON EQUITY (ROE) AVG TTM
-223.83%
RETURN ON EQUITY (ROE) AVG 3Y
-131.17%
RETURN ON EQUITY (ROE) AVG 5Y
-108.26%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+30.60%
CURRENT VS 3Y AVG
-18.42%
CURRENT VS 5Y AVG
-43.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.94%
median of 397 covered companies
CURRENT VS SECTOR MEDIAN
-320.51%
vs the sector median at left
Cardiol Therapeutics Inc.
Market Cap
$152.16M
Return on Equity (ROE)
-155.34%
TTM Avg
-223.83%
3Y Avg
-131.17%
5Y Avg
-108.26%
Market Cap
$152.45M
Return on Equity (ROE)
-21.38%
TTM Avg
-42.33%
3Y Avg
-37.95%
5Y Avg
-45.57%
Market Cap
$153.84M
Return on Equity (ROE)
-183.44%
TTM Avg
-114.28%
3Y Avg
-67.72%
5Y Avg
-46.03%
Market Cap
$149.51M
Return on Equity (ROE)
-93.22%
TTM Avg
-92.28%
3Y Avg
-73.94%
5Y Avg
-53.80%
Market Cap
$146.66M
Return on Equity (ROE)
-30.03%
TTM Avg
-86.56%
3Y Avg
-69.53%
5Y Avg
-37.30%
Market Cap
$160.82M
Return on Equity (ROE)
-14.07%
TTM Avg
-16.23%
3Y Avg
-27.66%
5Y Avg
-19.01%
Market Cap
$142.49M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
Market Cap
$142.11M
Return on Equity (ROE)
-44.26%
TTM Avg
-34.18%
3Y Avg
285.39%
5Y Avg
-5868.11%
Market Cap
$162.82M
Return on Equity (ROE)
-59.40%
TTM Avg
-255.06%
3Y Avg
-160.44%
5Y Avg
-112.56%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiol Therapeutics Inc. (CRDL) | $152.16M | -155.34% | -223.83% | -131.17% | -108.26% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | -21.38% | -42.33% | -37.95% | -45.57% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | -183.44% | -114.28% | -67.72% | -46.03% |
| Codexis, Inc. (CDXS)vs › | $149.51M | -93.22% | -92.28% | -73.94% | -53.80% |
| Immuneering Corporation (IMRX)vs › | $146.66M | -30.03% | -86.56% | -69.53% | -37.30% |
| Inogen, Inc. (INGN)vs › | $160.82M | -14.07% | -16.23% | -27.66% | -19.01% |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.49M | 68.12% | -94.32% | -166.28% | -128.51% |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | -44.26% | -34.18% | 285.39% | -5868.11% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | -59.40% | -255.06% | -160.44% | -112.56% |
| Freenome, Inc. (FRNM)vs › | $137.29M | N/A | N/A | N/A | N/A |
ROE
-155.3%
ROA
-127.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -155.34% |
| 2026-03-31 | -150.99% |
| 2025-12-31 | -186.67% |
| 2025-09-30 | -335.02% |
| 2025-06-30 | -291.15% |
| 2025-03-31 | -185.24% |
| 2024-12-31 | -137.73% |
| 2024-09-30 | -312.16% |
| 2024-06-30 | -159.07% |
| 2024-03-31 | -125.39% |
| 2023-12-31 | -73.62% |
| 2023-09-30 | -81.67% |
| 2023-06-30 | -56.03% |
| 2023-03-31 | -64.41% |
| 2022-12-31 | -62.95% |
| 2022-09-30 | -41.76% |
| 2022-06-30 | -40.37% |
| 2022-03-31 | -38.10% |
| 2021-12-31 | -34.84% |
| 2021-09-30 | -100.51% |
| 2021-06-30 | -71.18% |
| 2021-03-31 | -110.43% |
| 2020-12-31 | -113.87% |
| 2020-09-30 | -45.78% |
| 2020-06-30 | -41.00% |
| 2020-03-31 | -97.81% |
| 2019-12-31 | -87.24% |
| 2019-09-30 | -116.86% |
| 2019-06-30 | -106.08% |
| 2019-03-31 | -85.92% |
| 2018-12-31 | -73.12% |
| 2018-06-30 | -335.14% |
| 2018-03-31 | -75.28% |
